about
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveDouble-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patientsSimultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin, p-aminohippuric acid and pindololThe effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individualsPotential fluconazole-induced carbamazepine toxicityFirst dose in neonates: are juvenile mice, adults and in vitro-in silico data predictive of neonatal pharmacokinetics of fluconazole.Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant.Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidationDosage adjustment of fluconazole during continuous renal replacement therapy (CAVH, CVVH, CAVHD, CVVHD).Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients.Fluconazole pharmacokinetics in burn patientsPharmacokinetics of orally administered antifungals in onychomycosis.The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a review.Voriconazole: a new triazole antifungal.Effect of fluconazole on the pharmacokinetics of doxorubicin in nonhuman primates.Rationale for combination antifungal therapy.Human pharmacogenomic variations and their implications for antifungal efficacy.Fluconazole: optimized antifungal therapy based on pharmacokinetics.Pharmacokinetics and bioavailability of fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infectionSubstrate specificity and ligand interactions of CYP26A1, the human liver retinoic acid hydroxylase.Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patientsPopulation pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets.Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers.Human subcutaneous tissue distribution of fluconazole: comparison of microdialysis and suction blister techniques.Effect of azole antifungals ketoconazole and fluconazole on the pharmacokinetics of dexloxiglumide.Pharmacokinetics and bioavailability of fluconazole in patients with AIDS.Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemiaMonitoring and impact of fluconazole serum and cerebrospinal fluid concentration in HIV-associated cryptococcal meningitis-infected patients.Drug interactions during therapy with three major groups of antimicrobial agents.Population pharmacokinetic analysis of fluconazole to predict therapeutic outcome in burn patients with Candida infectionFluconazole (Diflucan).What is the success of treatment of hip and knee candidal periprosthetic joint infection?Population Pharmacokinetics of Fluconazole in Premature Infants with Birth Weights Less than 750 Grams.The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agents in vitro.Antifungals to treat Candida albicans.Pharmacokinetic evaluation of fluconazole in critically ill patients.Update on drug interactions with azole antifungal agents.Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Fluconazole plasma concentration measurement by liquid chromatography for drug monitoring of burn patients.Fluconazole penetration into the human prostate.
P2860
Q27009221-CDA7D971-F304-4871-A541-583DD92F2D82Q28362691-5E49ED41-8D11-42E3-AA26-B99528DE2AC3Q28367555-AB4AB7FE-4683-401A-A84D-25F1F83B8F0AQ28367578-310E10D2-6189-47D4-961C-321A2D13879CQ28371958-43F5C33E-8B7E-4C8A-AB0E-4AE5AF47ED54Q30844731-6319D613-0A54-41E6-A0E2-EC17B9F05804Q31012256-7B732EEB-6BBA-467A-A9AA-339055FF8CE3Q31034463-08B6ACAD-7C7F-4B07-ADBB-CACE2D598354Q33680344-F39E617D-F67F-4431-93B1-12678A64E56DQ33689354-C6D08A5D-0BF5-4B2D-80E8-9FC123CE6600Q33692868-C47FB846-1397-43A6-8E60-E8897EFF992AQ33749022-49F1851D-51FA-4D55-90CD-EB30C6DA97F9Q33788619-6E4E03ED-CB5B-4A4A-B2FE-207BB405BF2AQ33917339-0C91784A-CC30-466A-91FB-6F634814E211Q33979288-13CEF4B8-DD39-4C1E-B525-91A94FBBD245Q34335236-7252A493-7439-4D9C-98DA-295E3B7CE3A3Q35070838-01FB0E43-F212-4E9B-91E8-E186E88A410EQ35105390-13AC2272-DDC7-488B-905B-B02728D985A1Q35117518-98A7816A-6190-4B36-B7E6-9126F3C00C31Q35122815-03F9F9BC-0FCF-45AE-8822-DCDB2EA08DB0Q35137986-F5F5718B-81FB-4787-BADD-4B9A8F932AF9Q35598414-C24E3354-6E15-4F2E-93C3-C42F69B03DC8Q35635971-22C102A5-0616-4D93-B07B-25480AB12B7FQ35825795-9B80A95F-7E78-4C44-91C2-FA7A6074C19BQ35827197-B3C87EDB-4692-4CA8-8452-4E18D27875D5Q35897483-ACE8FE44-26EB-4B6E-9E16-0BE4A8C6FC64Q36094974-ADA49F83-FDA7-4595-B2DC-D9E7AC65A48DQ36161724-D5169F1C-E139-4A9C-B2A3-5581EDB9FBD9Q36429699-B43180D3-A5CB-4AAD-B190-5EFF05FB470EQ36558341-CE1BCAF4-FB65-4E27-8ABA-8A7BB2A9FEA3Q36624924-6228F2D4-9BAC-4FE0-BB24-12B94745A76CQ37072292-2BE23489-C031-4D17-8CA6-EC2A92841552Q37203784-33740289-FD7A-447E-903B-F8B79A517A16Q37700546-0458EC5B-69CC-47E6-BEF1-282D7E71373EQ37763928-F167A944-D7D0-4CAB-8732-9519D61E0B70Q37924819-784514F9-17EC-4898-ACF4-58F9E3BE8555Q38549824-93A97476-B985-42FC-9499-8519FB91D87BQ38681635-B402FF51-116B-42E5-B2DF-27C16E73F359Q39242940-89CD189A-41D6-438C-A67C-1CFB43BC5438Q39779244-5755095A-DE71-4025-94BE-EA1C5B22D7E2
P2860
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Clinical pharmacokinetics of fluconazole.
@en
type
label
Clinical pharmacokinetics of fluconazole.
@en
prefLabel
Clinical pharmacokinetics of fluconazole.
@en
P1476
Clinical pharmacokinetics of fluconazole.
@en
P2093
D Debruyne
J P Ryckelynck
P356
10.2165/00003088-199324010-00002
P577
1993-01-01T00:00:00Z
P6179
1010406135